je.st
news
Tag: phase
Phase Control Thyristors handle currents up to 25 A.
2014-07-03 14:31:02| Industrial Newsroom - All News for Today
Supplied in standard TO-48 package, 25RIA Series ranges from 100–1,200 V with max repetitive peak and off-state voltage from 100–1,200 V. Stud-style devices feature max non-repetitive peak voltage range of 150–1,300 V and max on-state voltage of 1.70 V. DC gate current required to trigger is 60 mA. Operating from -65 to +125°C, single-phase silicon controlled rectifiers provide optimized glass passivation and are suited for AC/DC converters, DC power supplies, and machine tool controls. This story is related to the following:Phase Control Thyristors | Silicon Controlled Rectifiers (SCR)
Teams Drive Detailed Construction Planning Into the Design Phase
2014-07-02 22:13:43| ENR.com: Headline News
Teams using advanced work packaging techniques have realized 25% improvement in productivity, 10% reduction in total installed cost and better safety performance on projects.
Tags: design
drive
planning
construction
Small Diameter Bomb II Nears End Of Development Phase
2014-07-01 11:49:12| rfglobalnet News Articles
Raytheon Company (NYSE:RTN) and the U.S. Air Force concluded a series of flight tests for theSmall Diameter Bomb IIculminating in direct hits on stationary land targets.
Tags: end
small
development
phase
Saelig Introduces Digital Phase Shifter USB RF Modules For Economical Configurable RF Test Measurements
2014-07-01 08:34:19| rfglobalnet News Articles
Saelig Company, Inc. announces the availability of theTelemakus TEP2000-4andTEP4000-5 Digital Phase Shifters- the smallest USB microwave phase shifters available and priced significantly below other market offerings.
Merck Announces Data from Investigational Phase 3 Study on EMEND (aprepitant) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children Undergoing Emetogenic Chemotherapy
2014-06-30 14:00:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. Merck Planning Regulatory Submissions in the U.S. for EMEND in Pediatric Setting Including New Suspension Formulation in Second Half of 2014 WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from a global, investigational Phase 3 study to evaluate the safety and efficacy of EMEND (aprepitant) in the prevention of chemotherapy-induced nausea and vomiting (CINV) in pediatric cancer patients, aged 6 months to 17 years. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558orClaire Mulhearn, 908-423-7425orInvestors:Joseph Romanelli, 908-423-5185orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
study
children
phase
Sites : [164] [165] [166] [167] [168] [169] [170] [171] [172] [173] [174] [175] [176] [177] [178] [179] [180] [181] [182] [183] next »